## 1 Short report

- 2 Title: Efficacy of N-163 strain of Aureobasidium pullulans-produced beta-glucan in
- 3 improving muscle strength and function in patients with Duchenne muscular dystrophy;
- 4 Results of a 6-month non-randomised open-label linear clinical trial
- 5 **Running Title**: N-163 beta glucan in DMD improves muscle function

## 6 Authors:

- 7 Kadalraja Raghavan<sup>1</sup> (<u>drkraghavan@nichimail.jp</u>)
- 8 Thanasekar Sivakumar<sup>1</sup> (<u>siva.ctg@gmail.com</u>)
- 9 Sudhakar S Bharatidasan<sup>2</sup> (<u>drsudhakar77@gmail.com</u>)
- 10 Subramaniam Srinivasan<sup>3</sup> (<u>masala76@gmail.com</u>)
- 11 Vidyasagar Devaprasad Dedeepiya<sup>3</sup> (<u>drddp@nichimail.jp</u>)
- 12 Nobunao Ikewaki<sup>4,5</sup> (<u>nikewaki@phoenix.ac.jp</u>)
- 13 Rajappa Senthilkumar<sup>6,7</sup> (<u>rsk@nichimail.jp</u>)
- 14 Senthilkumar Preethy<sup>6</sup> (drspp@nichimail.jp)
- 15 Samuel JK Abraham<sup>3,7,8,9,10</sup> (<u>drsam@nichimail.jp</u>)

# 16 Affiliations:

- 17 1. Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for
- 18 Advanced Recovery and Education (JAICARE), Madurai, India
- 19 2. Department of Anesthesia, Thunder Bay Regional Health Sciences Centre, Thunder
- 20 Bay, Ontario, Canada

22	3. Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative
23	Medicine (NCRM), Chennai, India.
24	4. Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
25	5. Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
26	6. Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine
27	(NCRM), Chennai, India.
28	7. Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,
29	Japan.
30	8. Centre for Advancing Clinical Research (CACR), University of Yamanashi - School
31	of Medicine, Chuo, Japan.
32	9. R & D, Sophy Inc., Japan
33	10. Levy-Jurgen Transdisciplinary Exploratory (LJTE), Global Niche Corp., Wilmington,
34	DE, USA
35	
36	
37	Corresponding author information:
38	Dr. Samuel JK Abraham,
39	II Department of Surgery & CACR,
40	University of Yamanashi, Faculty of Medicine
41	Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan
42	Email id- drsam@nichimail.jp; Alternate email id: drspp@nichimail.jp
43	Fax: +81-55-235-7569

## 45 **Declarations:**

#### 46 *Ethics approval and consent to participate*

- 47 The study was registered in Clinical trials registry of India, CTRI/2022/05/042905 and
- 48 approved by the ethics committee of Saravana Multispeciality Hospital-Institutional Ethics
- 49 Committee, India
- 50 Consent for publication
- 51 Not applicable
- 52 Availability of data and material
- All data generated or analysed during this study are included in the article itself.

#### 54 Funding

55 No external funding was received for the study

## Competing

## interests

Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans.

## 56 *Authors' contributions*

- 57 KR, NI and SA. contributed to conception and design of the study. KR and RS helped in data
- collection and analysis. SA and SP drafted the manuscript. VD, SS and SB performed critical
- revision of the manuscript. All authors read and approved the final manuscript.

### 60 Acknowledgements

61 The authors thank

62	1.	The Government of Japan and the Prefectural Government of Yamanashi for a special
63	loan ai	nd M/s Yamanashi Chuo Bank for processing the transactions.
64	2.	Ms. Sunitha, Mr. Vincent and the staff of JAICARE and Sarvee Integra, Dr.
65	Ragaro	pobine, Mr. Rajmohan from Nichi-In Centre for Regenerative Medicine (NCRM) for
66	their a	ssistance during the clinical study and data collection of the manuscript.
67	3.	Fr. Francis Xavier, Rector, Loyola College, Chennai, Fr. Vargheesh Antony and Fr.
68	Maria	nathan of JAICARE for their support during the clinical study.
69	4.	Ms. Misa Takamoto, Mr. Masato Onaka, Mr. Yasushi Onaka of Sophy Inc, Kochi,
70	Japan	for necessary technical support.
71	5.	Ms. Yoshiko Amikura and staff of GN Corporation, Japan for their liaison assistance
72	with th	ne conduct of the study.
73	6.	Loyola-ICAM College of Engineering and Technology (LICET) for their support to
74	our res	search work.
75		
76		
77		
78		
79		
80		
81		
82		

## 83 Abstract:

84 Duchenne muscular dystrophy (DMD) is a debilitating genetic disease that causes gradual 85 muscle weakening and early mortality. After a 45-day clinical pilot study and a pre-clinical 86 study in mdx mice demonstrating safety and efficacy, and anti-fibrotic and anti-inflammatory 87 effects, respectively, of an Aureobasidium pullulans N-163 strain-produced B-1,3-1,6-88 glucan. We conducted this linear six-month clinical study to assess its efficacy. Twelve 89 ambulatory and 12 non-ambulatory individuals with DMD were included; all received the N-90 163 strain of A.pullulans produed beta-glucan dietary supplement orally in addition to the 91 standard treatment regimen, which included steroids. The Medical Research Council muscle 92 score improved in 11 patients in the ambulatory group and in 8 patients in the non-93 ambulatory group. The six-minute walk test distance improved in nine patients, with a 29.5-94 meter average improvement. The North Star Ambulatory Assessment improved by 1 unit in 95 three patients. This safe beta-glucan food supplement improved muscle function within 6 96 months. A comprehensive, multi-centric clinical research should be conducted for unravelling 97 its potential as a disease- modifying drug adjuvant in DMD.

98

99 Keywords: Duchenne muscular dystrophy; N-163; beta glucan; disease modifying agent; 6100 minute walk test

## 101 Introduction:

102 Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive disease, whose prevalence varies between 1 in 3600 and 1 in 9300 male infants globally.<sup>1</sup> Loss-of-function 103 104 mutations in the DMD gene prevent the production of functional dystrophin protein in 105 patients with DMD, which causes progressive skeletal muscle weakening and degeneration, heart dysfunction, respiratory failure, and ultimately premature death.<sup>1,2</sup> The two treatment 106 approaches for DMD are as follows: the first is dystrophin-targeted therapy, and the 107 108 alternative is to focus on the pathological alterations that occur downstream. Gene, cell, and 109 protein replacement therapies are examples of treatments that target dystrophin. However, 110 dystrophin-targeted therapy can only slow the course of the disease and cannot restore the 111 function of defective muscle tissues. Second, owing to the body's widespread distribution of muscle tissue, dystrophin-targeted medicines have difficulty reaching all muscle tissues.<sup>3</sup> 112 113 Targeting secondary downstream pathological mechanisms is another therapeutic approach. 114 Multiple pathogenic processes, such as fibrosis, inflammation, loss of calcium homeostasis, 115 oxidative stress, ischaemia, and muscular atrophy, are triggered by downstream pathological mechanisms.<sup>3</sup> Different approaches that target fibrosis, inflammation, ischaemia, etc., are 116 117 available, although a wholesome approach to DMD that aims both at dystrophin replacement 118 as well as addressing downstream pathological mechanisms is necessary.

Previously, we have reported on a 1-3,1-6 beta-glucan from the N-163 strain of the black yeast *Aureobasidium pullulans* that helped decrease interleukin (IL)-6, tumour growth factor (TGF)- $\beta$ , and IL-13 and increase dystrophin levels along with improvement of muscle strength in patients with DMD in a clinical study performed in 28 patients with DMD for a duration of 45 days.<sup>4</sup> In the same study, we reported the beneficial constitution of the gut microbiome with an increase in butyrate-producing species such as *Roseburia* and *Faecalibacterium prausnitzii*, apart from a decrease in harmful bacteria associated with

inflammation such as enterobacteria and *Alistipes*.<sup>5</sup> We also conducted a pre-clinical study of 126 127 this N-163 beta-glucan in an mdx mice model, which revealed a significant decrease in 128 inflammation score and fibrosis as well as levels of plasma alanine transaminase, aspartate 129 aminotransferase, lactate dehydrogenase, IL-13, and haptoglobin; increased anti-130 inflammatory TGF- $\beta$  levels; and balanced regulation of the quantity of centrally nucleated fibres indicative of muscle regeneration.<sup>6</sup> In a pre-clinical study of mdx mice, we also 131 132 reported muscle regeneration and maturation by MYH3 and CD44 expression.<sup>7</sup> In the present 133 study, we evaluated the effects of N-163 beta-glucan for 6 months in patients with DMD.

## 134 Materials and methods:

This trial was an investigator-initiated, single-centre, randomised, open-label, prospective,
linear, single-arm clinical study of patients with DMD. This study was conducted over a
period of 180 days.

The intervention was consumption of one sachet of N-163 beta-glucan (Commercial name:
Neu-REFIX) once daily along with conventional treatment comprising routine physiotherapy
for joint mobility along with medications, viz., T. calcium and vitamin D 1000 with or
without deflazacort (steroid) 6–24 mg.

#### 142 Inclusion criteria:

This study included male patients with a molecular diagnosis of DMD aged 3–30 years who
were willing to participate in the study with written informed consent.

## 145 *Exclusion criteria*:

Patients with a previous (within the past 1 month) or concomitant participation in any othertherapeutic trial; a known or suspected malignancy; any other chronic disease, or clinically

148 relevant limitation of renal, liver, or heart function according to the discretion of the 149 investigator were excluded from the study.

#### 150 Investigations:

A background survey was conducted to obtain data on sex, date of birth, age, habits, current medical history, medication, treatment, allergies (to drugs and food), regular use of food for specified health uses, functional foods, health foods, intake of foods rich in beta-glucan and foods containing beta-glucan, and intake of immunity-boosting foods. Medical history and physical measurements were taken, including height, weight, body mass index, and temperature. The following tests were performed at baseline and at the end of the study (6 months).

- Physiological examination included assessing the systolic blood pressure, diastolic
   blood pressure, and pulse rate.
- 160 2. Electrocardiogram (ECG).
- 161 3. The Medical Research Council (MRC) Scale was used to measure muscle strength.

4. six-minute walk test (6MWT) and North Star Ambulatory Assessment (NSAA)

163 The participants were contacted every week for drug compliance and the recording of adverse164 effects, if any.

165 At 3 and 6 months, a physiological examination was performed to assess systolic blood 166 pressure, diastolic blood pressure, and pulse rate.

## 167 Statistical analysis:

Microsoft Office Excel statistics package and the software Origin 2021b were used for statistical analysis. Statistical significance was set at p<0.05, and multiple comparisons or multiple outcomes were not corrected.

## 171 **Results:**

172 Altogether, 27 patients were screened, of whom 24 were included in the study. The mean  $\pm$ 173 standard deviation of age for the total study population was  $11.33 \pm 4.57$  years (range, 5–26 174 years).

No adverse events were observed. No clinically significant changes from baseline data were
observed on physical examination or in vital signs—temperature, blood pressure, oxygen
saturation, pulse rate, or ECG (data not shown).

The mean NSAA score at pre-intervention  $(21.41 \pm 11.81)$  and post-intervention  $(21.58 \pm 11.87)$  did not indicate any significant change. The NSAA score improved by 1 unit in three patients and decreased by 1 unit in one patient. In the remaining patients, no change was identified (Figure 1). In the ambulatory group (n=12), the MRC score improved in 11 patients, with an average improvement of 7.09%, while it increased by 9.27% in 8 of the 12 non-ambulatory patients and decreased in 2 cases (Figure 2). The 6MWT distance improved in 9 patients, with a 29.5-metre average improvement (Figure 3).

## 185 **Discussion:**

186 The goal of DMD treatment is to correct genetic defects and restore muscle function apart from re-establishing normal levels of dystrophin.<sup>1-3</sup> Despite some approaches being in 187 188 clinical trials, gene correction therapies such as exon-skipping therapies are available only for 189 a select group of patients with specific exon deletions. Although supportive treatments aim to 190 halt or delay the disease progression, they do not significantly contribute to muscle 191 regeneration and the restoration of muscle function, apart from the associated side effects. 192 Even in long-term studies, only in terms of delaying the disease progression, positive 193 outcome was reported without any improvement of muscle strength or function after the intervention compared to the baseline data in the treatment arm<sup>8</sup>. One of the reasons for the 194

lack of adequate muscle regeneration is inflammation.<sup>1-3</sup> Since we have earlier proven the decrease in inflammation through biomarker levels in clinical and pre-clinical studies,<sup>4-6</sup> restoration of gut microbiome<sup>6</sup>, and muscle regeneration after consumption of N-163 strain of *Aureobasidium pullulans* produced beta-glucan evident from increased MYH3 expression and proper muscle maturation by increased CD44 hyaluronan expression in an mdx mice model,<sup>7</sup> which could be attributed to the clinical improvement in muscle strength and function in the present study.

In our present study of only six months, the 6MWT distance improved in 9 patients, with a 203 29.5-metre average improvement. Although the NSAA scores did not indicate any significant 204 differences pre- and post-intervention, the improvement in MRC grading in 91.6% of the 205 participants, apart from improvement in the 6MWT indicates the significance of this N-163-206 produced beta-glucan approach in terms of muscle function improvement, which is not 207 commonly observed with conventional or even other recent therapeutic approaches.

The limitations of this study are its smaller sample size and heterogeneity of the standard treatment regimens followed and a duration of six-months. Nevertheless, the safety and muscle function improvement efficacy of this N-163-produced beta-glucan food supplement without adverse reactions can be considered an indispensable addition to disease-modifying treatments for DMD and other dystrophies, such as limb-girdle muscular dystrophy.

#### 213 **Conclusion:**

This safe N-163 strain of *Aureobasidium pullulans* produced beta-glucan food supplement is a promising disease-modifying pharmacological adjuvant in DMD, as it improved MRC in 91.6% of the patients, with modest improvements in 6MWT and NSAA score after 6 months. In the future, a comprehensive, multi-centric clinical study should be conducted to unravel

- the potentials of this orally consumable, safe, and allergen-free food supplement as a drug
- adjuvant in delaying the progression of DMD and other dystrophies.
- 220
- 221
- 222
- 223 Abbreviations:
- 224 DMD: Duchenne muscular dystrophy
- 225 6MWT: Six-minute walk test
- 226 NSAA: North Star Ambulatory Assessment
- 227 MRC: Medical Research Council
- 228

229


## 230 **References:**

231	1.	Liew WK, Kang PB. Recent developments in the treatment of Duchenne muscular
232		dystrophy and spinal muscular atrophy. Ther Adv Neurol Disord. 2013 May;6(3):147-
233		60.
234	2.	Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, McDonald CM, Smith
235		EC, Zaidman CM, Nakagawa T; CINRG DNHS Investigators; Hoffman EP. Long-
236		Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne
237		Muscular Dystrophy. J Neuromuscul Dis. 2022;9(4):493-501.

- Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G, Zhang Z, Zhang B. Current
   Pharmacological Strategies for Duchenne Muscular Dystrophy. Front Cell Dev Biol.
   2021 Aug 19;9:689533
- 241 4. Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Disease-modifying immune-242 243 modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-244 245 label. prospective, randomized. comparative clinical study.medRxiv 2021.12.13.21267706; doi: 10.1101/2021.12.13.21267706 246
- 5. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A,
  Senthilkumar R, Preethy S, Abraham SJK. Randomised trial of Aureobasidium
  pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular
  dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating
  their potential in epigenetic manipulation. medRxiv 2022.12.09.22283273; doi:
  10.1101/2022.12.09.22283273
- Preethy S, Aoki Y, Minegishi K, Senthilkumar R, Abraham S. Resolution of fibrosis
  in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium
  pullulans produced biological response modifier β-glucan (BRMG). bioRxiv
  2022.11.17.516628; doi: 10.1101/2022.11.17.516628
- Abraham S, Sakamoto S, Higuchi T, Srinivasan S, Dedeepiya VD, Ikewaki N,
   Iwasaki M, Rajmohan M, Senthilkumar R, Preethy S. Enhanced muscle regeneration
   in MDX Duchenne muscular dystrophy-mice, proven by CD44 & MYH3, on
   consumption of A.Pullulans produced Neu REFIX β-Glucan. MDA Conference 2023,
   Dallas, Texas, USA.

262	8.	Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig
263		E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F; SKIP-NMD Study
264		Group. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients
265		with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-
266		human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Ther. 2022
267		Feb;32(1):29-39.
268		
269		
270		
271		
272		
273		
274		
275		
276		
277		
278		
279		
280		
281		
282		

# 283 Figures



# North Star Ambulatory Assessment Score

284

285 Figure 1: North Star Ambulatory Assessment Score pre- and post-intervention of N-163

- 286 beta-glucan in patients with Duchenne muscular dystrophy.
- 287

288

- 289
- 290

291




Figure 2: Medical Research Council grading pre- and post-intervention of N-163 betaglucan in patients with Duchenne muscular dystrophy.




Figure 3: Six-minute walk test score pre- and post-intervention of N-163 beta-glucan in

324 patients with Duchenne muscular dystrophy.